SCHEMBL29590481

SCHEMBL29590481

CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CO)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 5/20 0.48
▸ NPY1R P25929 4/20 0.48
▸ NPY2R P49146 3/20 0.48
▸ NMT2 O60551 1/20 0.47
▸ NMT1 P30419 1/20 0.47
▸ TASP1 Q9H6P5 1/20 0.45
▸ GRIN2D O15399 1/20 0.44
▸ GRIN3B O60391 1/20 0.44
▸ GRIN1 Q05586 1/20 0.44
▸ GRIN2A Q12879 1/20 0.44
▸ GRIN2B Q13224 1/20 0.44
▸ GRIN2C Q14957 1/20 0.44
▸ GRIN3A Q8TCU5 1/20 0.44
▸ FOLH1 Q04609 2/20 0.44
▸ NPY5R Q15761 2/20 0.42
▸ NOD1 Q9Y239 1/20 0.42
▸ CPB2 Q96IY4 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ MME P08473 3/20 0.41
▸ ERAP2 Q6P179 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29630455 0.99 NPY4R (0.47) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL31343260 0.94 NPY4R (0.51) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL30388451 0.94 NPY4R (0.51) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL29630544 0.92 NMT2 (0.47) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL31314472 0.92 FOLH1 (0.47) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL31094979 0.92 NPY4R (0.48) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL29679551 0.91 NMT2 (0.46) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL29354569 0.91 MME (0.48) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL31593295 0.90 NMT1 (0.45) NPY4RNPY1RNPY2RNMT2NMT1
SCHEMBL29680077 0.90 FOLH1 (0.51) NPY4RNPY1RNPY2RGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12618102-B2 Biochemical reaction methods and reagents comprising intrinsically disordered regions Biocrucible Limited (GB) 2026-05-05 — — US disclosed
US-20220112547-A1 BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS Biocrucible Limited (GB) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12618102-B2 Biochemical reaction methods and reagents comprising intrinsically disordered regions POLM, POLR1A, POLR1E NPY4R 4433/4885NPY1R 3079/4885NPY2R 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback